There has been a steady stream of encouraging data on stem cells for MS. Particularly for certain kinds of MS. A new study adds to this upbeat direction. Good news on stem cells for MS Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study, Journal of Neurology, Neurosurgery, […]
Weekly reads: stem cells for MS, Kimera Labs IND, FDA lawsuit Read More »
I’m kind of in grant writing hell at the moment, as many of you may have been at various times, but I’m still finding time to read a little on cell therapy and stem cell research. Here are some things that caught my eye as I work on multiple grants with impending deadlines. Clinical trials
Weekly reads: cell therapy trials, melanoma, β-thalassemia Read More »
Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might
Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »
Almost two years ago I publicly called on the FDA to freeze the unproven cord cell expanded access program (EAP) at the Duke Autism Center. Duke has been infusing kids with autism spectrum disorder (ASD) with unproven cord cells and requiring large payments for this. The cost was as much as $15,000. A halt and a
Why did Duke autism team halt its troubling pay-for-play program? Read More »
Are there endogenous adult heart stem cells that are useful in cardiac disease or can stem cell infusions help ailing hearts? As to the first question, the adult heart does not appear to have meaningful numbers of true stem cells. Further, testing the idea of infusions of stem cells for heart disease has so far been giving
Heart stem cells trial mostly disappoints but is oversold Read More »
Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they
2023 stem cell & regenerative medicine predictions Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
An FDA FOIA dump of text messages of former Commissioner Stephen Hahn suggests that a Texas regenerative firm called Direct Biologics benefited from political pressure on him in mid-2020. Then he was asked again to help in early 2021. This was shortly before he resigned at the start of the Biden Administration. The push came from
FDA leader Stephen Hahn was pressured to aid Texas firm Direct Biologics Read More »
Stem cell biologist Jacob Hanna has a new startup called Renewal Bio. Its goal is to harvest cells or tissues from human embryo or fetus models for clinical use. I believe that their commercial ambitions have so far outstripped careful thought and discussion in the broader community of researchers. There are major risks here for
‘We don’t want to freak people out’: about that Jacob Hanna human embryo model startup Read More »